Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure
NCT05633758 · Scripps Health · PHASE2 · withdrawn · last registry update 2022-12-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “no participants enrolled” | – | Registry record, Scripps Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-25Results posted on the registry: University of Texas Southwestern Medical Center, Potassium Magnesium Citrate (KMgCit) + Potassium Chloride (KCl) (NCT02665117)
- 2023-10-24Also stopped (terminated): Novartis, Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 + Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 (NCT00170950)
- 2023-10-13Also stopped (withdrawn): Northwestern University, Amlodipine Besylate + Chlorthalidone (NCT05275907)
- 2023-09-22Results posted on the registry: Washington University School of Medicine, QUARTET LDQT + Candesartan (NCT03640312)
- 2023-08-21Results posted on the registry: Tulane University School of Medicine, amlodipine, hydralazine, terazosin or hydrochlorothiazide (NCT02046395)
- 2023-06-27Phase 3 first posted: Hospital Israelita Albert Einstein, candesartan cilexetil + chlorthalidone + amlodipine + Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) (NCT05920005)
- 2023-05-26Phase 3 first posted: Boryung Pharmaceutical Co., Ltd, Fimasartan + Indapamide + Fimasartan + Indapamide placebo (NCT05878561)
- 2023-05-03Also stopped (withdrawn): Ochsner Health System, Furosemide plus Chlorothiazide + Furosemide (NCT05840536)
- 2023-04-20Phase 3 first posted: Institut de Recherches Internationales Servier, Fixed [Per/Ind/Aml] + Free [Per/Ind + Aml] (NCT05820880)
- 2023-04-14Results posted on the registry: Gary L. Pierce, Clonidine + Hydrochlorothiazide (NCT01983462)
- 2023-04-14Also stopped (terminated): Gary L. Pierce, Clonidine + Hydrochlorothiazide (NCT01983462)
- 2022-10-14Phase 3 first posted: Instituto Nacional de Cardiologia Ignacio Chavez, Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID + Empagliflozin 10 MG OD (NCT05580510)
- 2022-09-19Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sacubitril/valsartan + valsartan (NCT05545059)
- 2022-09-09Results posted on the registry: The University of Texas Health Science Center, Houston, Amlodipine + Lisinopril (NCT03461003)
- 2022-07-27Also stopped (suspended): EMS, Indapamide / Losartan + Indapamide / Losartan (NCT01620788)
- 2022-07-27Also stopped (withdrawn): EMS, LENINGRADO association + Indapamide SR 1.5 MG (NCT03814109)
- 2022-05-13Phase 3 first posted: University Medical Center Groningen, Hydrochlorothiazide 25 mg + Placebo (NCT05373264)
- 2022-03-31Results posted on the registry: Indiana University, Chlorthalidone + Placebo (NCT02841280)
- 2022-01-20Phase 3 first posted: Hanmi Pharmaceutical Company Limited, HCP1904-3 + RLD2001-1 (NCT05199129)
- 2021-12-15Also stopped (withdrawn): University Hospital Tuebingen, Dapagliflozin (Forxiga®) + Hydrochlorothiazide 25 mg (NCT03423355)
- 2021-12-09Also stopped (withdrawn): VA Office of Research and Development, Diuretic initiation or augmentation (NCT04192110)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision